CAMK2G and catecholaminergic polymorphic ventricular tachycardia 1: Our data demonstrate that genetically engineered resistance to CaMKII MM281/282 oxidation does not protect against arrhythmogenic Ca2+ release or arrhythmias in CPVT1.